Chennai Journal

Rheumatoid Arthritis Drugs Market Is Anticipated Lucrative Growth By Rising Penetration Of Generic Drugs Till 2025: Grand View Research, Inc.

 Breaking News
  • No posts were found

Rheumatoid Arthritis Drugs Market Is Anticipated Lucrative Growth By Rising Penetration Of Generic Drugs Till 2025: Grand View Research, Inc.

February 28
18:46 2018

Grand View Research, Inc. – Market Research And Consulting.
According to report published by Grand View Research, The global rheumatoid arthritis therapeutics market size is expected to reach USD 30.4 billion by 2025. Increasing launches of novel biologics and rising penetration of generic drugs are estimated to provide a significant boost to the market.

The global rheumatoid arthritis therapeutics market size is expected to reach USD 30.4 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.6% during the forecast period. Some of the key trends driving the market are availability of novel biologics, increase in potential clinical pipeline candidates, and rise in aging population. Thus, growing availability and awareness of safer drugs are projected to escalate rheumatoid arthritis drugs market growth. 

Rheumatoid arthritis affects approximately 1% of the global population. The condition has different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient’s mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.

Growing prevalence of the disease, presence of biologics & biosimilars, and well-defined regulatory guidelines are poised to provide a fillip to the market. According to the Arthritis Foundation, 64% of the population within the age group of 65 is likely to suffer from arthritis in U.S. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth.

Current treatment for rheumatoid arthritis includes generic pharmaceuticals such as NSAIDs and corticosteroids along with novel biologics such as JAK inhibitors and IL-6 antagonists, which are widely used in developed countries due to their high effectiveness. New product launches such as Infliximab and Adalimumab biosimilars are anticipated to work in favor of the market. Moreover, Eli Lilly’s Olumiant and AbbVie’s Upadacitinib are expected to cut down chances of disease remittance.

Full research report on rheumatoid arthritis therapeutics market  analysis:

U.S. rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Billion)

Further key findings from the report suggest:

  • North America held 56.6% of the market in 2016 due to rising awareness regarding disease treatment, growing geriatric population, and high adoption of biopharmaceuticals for treatment

  • Due to growing popularity, the biopharmaceuticals segment is projected to exhibit a CAGR of 8.3% during the forecast period

  • Prescriptions are anticipated to emerge as more reliable and a preferred sales channel over the same period

  • Asia Pacific is the most promising region, registering a CAGR of 9.5% between 2017 and 2025

  • Some of the key players in rheumatoid arthritis market are AbbVie; Boehringer Ingelheim GmbH; Novartis AG; Regeneron Pharmaceuticals, Inc.; Pfizer, Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; UCB S.A.; Johnson & Johnson Services, Inc.; and Amgen, Inc.

View more reports of this category by Grand View Research at:

Global rheumatoid arthritis therapeutics market revenue, by sales channel, 2016 (%)

Grand View Research has segmented the rheumatoid arthritis drugs/therapeutics market on the basis of molecule types, sales channels, and region:

Rheumatoid Arthritis Therapeutics Molecule Outlook (Revenue, USD Million, 2014 – 2025)

  • Pharmaceuticals

    • NSAIDs

    • Analgesics

    • DMARDs

    • Glucocorticoids

  • Biopharmaceuticals

    • Biologics

      • TNF-α antagonists

      • T-cell inhibitors

      • CD20 antigen

      • JAK inhibitors

      • anti-IL6 biologics

    • Biosimilars

      • CD20 antigen

      • TNF-α antagonists

Rheumatoid Arthritis Therapeutics Sales Channel Outlook (Revenue, USD Million, 2014 – 2025)

  • Prescription

  • Over-the-Counter (OTC)

Rheumatoid Arthritis Therapeutics Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa

Access Full Press Release of this Report:

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information:

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States

Related Articles